According to the announcement released by Suzhou Ribo Life Science Co., Ltd. (stock code: 06938, “RIBOLIFE-B”), the Board of Directors will convene on Wednesday, 25 March 2026.
The agenda includes: 1. Reviewing and approving the audited consolidated results for the financial year ended 31 December 2025 and authorising their publication. 2. Considering a recommendation for the payment of a final dividend, if any. 3. Handling other routine corporate matters.
The notice is signed by Chairman Dr. Liang Zicai and dated 12 March 2026 in Hong Kong. The Board currently comprises three executive directors, three non-executive directors and three independent non-executive directors.
Comments